Podocyte-specific overexpression of metallothionein mitigates diabetic complications in the glomerular filtration barrier and glomerular histoarchitecture: A transmission electron microscopy stereometric analysis

Diabetes/Metabolism Research and Reviews

Volumn 29, Issue 2, 2013, Pages 113-124

  Carlson, Edward C ^a   Chhoun, Jennifer M ^a   Laturnus, Donna I ^a   Bikash, Kc ^a   Berg, Brittany ^a   Zheng, Shirong ^b   Epstein, Paul N ^b  

^a UNIVERSITY OF NORTH DAKOTA   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Diabetic nephropathy; Endothelial fenestrations; Foot process width; Oxidative stress; TEM morphometry

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; METALLOTHIONEIN;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL COUNT; CELL DENSITY; CELL TYPE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GLOMERULAR FILTRATION BARRIER; GLOMERULUS BASEMENT MEMBRANE; GLUCOSE BLOOD LEVEL; KIDNEY MASS; MESANGIUM CELL; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; STEREOMETRY; TRANSMISSION ELECTRON MICROSCOPY;

ALBUMINURIA; ANIMALS; DIABETIC NEPHROPATHIES; GLOMERULAR BASEMENT MEMBRANE; GLOMERULAR FILTRATION BARRIER; KIDNEY GLOMERULUS; METALLOTHIONEIN; MICE; MICE, TRANSGENIC; MICROSCOPY, ELECTRON, TRANSMISSION; PODOCYTES;

EID: 84873494282     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2342     Document Type: Article

References (51)

1. The Diabetes Control IINA and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
3. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 29;107(9): 1058-1070.
4. Kashihara N, Haruna Y, Kanwar Y. Oxidative stress in diabetic nephropathy. Curr Med Chem 2010; 17(34): 4256-4269.
5. Prabhakar S, Starnes J, Shi S, Lonis B, Tran R. Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. J Am Soc Nephrol 2007; 18: 2945-2952.
6. Ha H, Yu M, Choi J, Lee B. Activation of protein kinase C-delta and C-epsilon by oxidative stress in early diabetic rat kidney. Am J Kidney Dis 2001; 38: S204-S207.
7. Vlassara H, Palace M. Diabetes and advanced glycation endproducts. J Intern Med 2002; 251: 87-101.
8. Wallner E, Wada J, Tramonti G, Lin S, Srivastava S, Kanwar Y. Relevance of aldo-keto reductase family members to the pathobiology of diabetic nephropathy and renal development. Ren Fail 2001; 23: 311-320.
9. Ziyadeh F. Mediators of diabetic renal disease: the case for TGF-beta as the major mediator. J Am Soc Nephrol 2004; 15(SUPPL 1): S55-S57.
10. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54(6): 1615-1625.
11. Vijayalingam S, Parthiban A, Shanmugasundaram K, Mohan V. Abnormal antioxidant status in impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabet Med 1996; 13: 715-719.
12. Wolff S, Jiang Z, Hunt J. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med 1991; 10: 339-352.
13. Baynes J. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-412.
14. Kawaguchi M, Yamada M, Wada H, Okigaki T. Roles of active oxygen species in glomerular epithelial cell injury in vitro caused by puromycin aminonucleoside. Toxicology 1992; 72: 329-340.
15. Zheng S, Carlson E, Yang L, Kralik P, Huang Y, Epstein PN. Podocyte-specific overexpression of the antioxidant metallothionein reduces diabetic nephropathy. J Am Soc Nephrol 2008; 19: 2077-2085.
16. Shah S. The role of reactive oxygen metabolites in glomerular disease. Annu Rev Physiol 1995; 57: 245-262.
17. Carlson E, Audette J, Klevay L, Nguyen H, Epstein P. Ultrastructural and functional analyses of nephropathy in calmodulin-induced diabetic transgenic mice. Anat Rec 1997; 247: 9-19.
18. Carlson E, Audette J, Veitenheimer N, Risan J, Laturnus D, Epstein P. Ultrastructural morphometry of capillary basement membrane thickness in normal and transgenic diabetic mice. Anat Rec 2003; 271A: 332-341.
19. Zheng S, Noonan W, Metreveli N, et al. Development of late-stage diabetic nephropathy in OVE26 diabetic mice. Diabetes 2004; 53(12): 3248-3257.
20. Teiken J, Audette J, Laturnus D, Zheng S, Epstein P, Carlson E. Podocyte loss in aging OVE26 diabetic mice. Anat Rec 2008; 291: 114-121.
21. Teiken J, Epstein P, Carlson E. TEM stereometric analyses of glomeruli in aging OVE26 transgenic diabetic mice. Am J Nephrol 2011; 33(SUPPL 1): 8-14.
22. Xu J, Huang Y, Li F, Zheng S, Epstein P. FVB mouse genotype confers susceptibility to OVE26 diabetic albuminuria. Am J Physiol Renal Physiol 2010; 299(3): F487-F494. Epub 2010 Jul 7.
23. Epstein P, Overbeek P, Means A. Calmodulin-induced early-onset diabetes in transgenic mice. Cell 1989; 58: 1067-1073.
24. Baur P, Stacey T. The use of PIPES buffer in the fixation of mammalian and marine tissues for electron microscopy. J Microsc 1977; 109: 315-327.
25. Karnovsky M. A formaldehyde-glutaraldehyde fixitive for high osmololity for use in electron microscopy. J Cell Biol 1965; 35: 137A-138A.
26. Venable J, Coggeshall R. A simplified lead stain for use in electron microscopy. J Cell Biol 1965; 25: 407-408.
27. Toyoda M, Najafian B, Kim Y, Caramori M, Mauer M. Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes 2007; 56: 2155-2160.
28. Dische F. Measurement of glomerular basement membrane thickness and its application to the diagnosis of thin-membrane nephropathy. Arch Pathol Lab Med 1992; 116: 43-49.
29. Jensen E, Gunderson H, Osterby R. Determination of membrane thickness distribution from orthogonal intercepts. J Microsc 1979; 115: 19-33.
30. Mifsud S, Allen T, Bertram J, et al. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia 2001; 44: 878-882.
31. Weibel E, Gomez D. A principle for counting tissue structures on random sections. J App Physiol 1962; 17: 343-348.
32. Weibel E. Stereological Methods, Vol. 1: Practical Methods for Biological Morphometry. Academic Press: London, 1979; 44-45.
33. White K, Bilous R. Estimation of podocyte number: a comparison of methods. Kidney Int 2004; 66: 663-667.
34. Basgen J, Nicholas S, Mauer M, Rozen S, Nyengaard J. Comparison of methods for counting cells in the mouse glomerulus. Nephron Exp Nephrol 2006; 103e: 139-e148.
35. Viberti G, Wiseman M, Pinto J, Messent J. Diabetic Nephropathy in Joslin's Diabetes Mellitus 13th Edn. Kahn CR, Weir GC (eds). Lea & Febiger: Philadelphia, 1994; 691-737.
36. Drummond K, Mauer M. International Diabetic Nephropathy Study Group. The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. Diabetes 2002; 51: 1580-1587.
37. Dalla Vestra M, Masiero A, Roiter A, Saller A, Crepaldi G, Fioretto P. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes 2003; 52: 1031-1035.
38. Pagtalunan M, Miller P, Jumping-Eagle S, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99: 342-348.
39. Shirato I, Hishiki T, Tomino Y. Podocyte loss and progression of diabetic nephropathy. Contrib Nephrol 2001; 134: 69-73.
40. Petermann A, Pippin J, Krofft R, et al. Viable podocytes detach in experimental diabetic nephropathy: potential mechanism underlying glomerulosclerosis. Neph Exp Nephrol 2004; 98: E144-E.
41. Susztak K, Raff A, Schiffer M, Bottinger E. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006; 55: 225-233.
42. Kriz W, Gretz N, Lemley K. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 1998; 54: 687-697.
43. Kralik P, Long Y, Song Y, et al. Diabetic albuminuria is due to a small fraction of nephrons distinguished by albumin-stained tubules and glomerular adhesions. Am J Pathol 2009; 2175(2): 500-509. Epub 2009 Jul 2.
44. Kobayashi M, Takaya S, Koie H, Nagai K. Glomerular endothelial changes in cyclosporine A-treated rats: scanning and transmission electron microscopic studies. Jpn J Surg 1991; 21(2): 210-215.
45. Chowdhury A. Participation of endothelial cells in the development of glomerulosclerosis: a study on murine serum sickness nephritis with mitomycin C. Pathol Int 1996; 46(3): 173-182.
46. Satchell S, Braet F. Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier. Am J Physiol Renal Physiol 2009; 296(5): F947-F956. Epub 2009 Jan 7.
47. Miner J. Glomerular basement membrane composition and the filtration barrier. Pediatr Nephrol 2011; Feb 15, E-pub ahead of print.
48. Tsilibary E. Microvascular basement membranes in diabetes mellitus. J Pathol 2003; 200: 537-546.
49. Binder C, Weiher H, Exner M, Kerjaschki D. Glomerular overproduction of oxygen radicals in Mpv17 gene-inactivated mice causes podocyte foot process flattening and proteinuria: a model of steroid-resistant nephrosis sensitive to radical scavenger therapy. Am J Pathol 1999; 154: 1067-1075.
50. Marshall C, Pippin J, Krofft R, Shankland S. Puromycin aminonucleoside induces oxidant-dependent DNA damage in podocytes in vitro and in vivo. Kidney Int 2006; 70(11): 1962-1973. Epub 2006 Oct 11.
51. Greiber S, Munzel T, Kastner S, Muller B, Schollmeyer P, Pavenstadt H. NAD(P)H oxidase activity in cultured human podocytes: effects of adenosine triphosphate. Kidney Int 1998; 53: 654-663.